Skip to search formSkip to main contentSkip to account menu

Myocet

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Doxorubicinliposome-encapsulated doxorubicin citrate complex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
EU-Zulassung für neuen Anti-CD20-Antikörper
2013
2013
Abstract P3-14-16: A phase 2 trial of myocet®, cyclophosphamide +/- trastuzumab followed by weekly paclitaxel +/- trastuzumab as primary systemic therapy in operable and locally advanced breast…
BACKGROUND: Anthracycline- and taxane-based chemotherapies are highly effective in primary systemic treatment of breast cancer… 
2012
2012
Abstract OT3-3-10: ASTER 70s: Benefit of adjuvant chemotherapy for oestrogen receptor-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade. A French UNICANCER Geriatric…
Background: Despite a high incidence of oestrogen receptor-positive (ER+) HER2-negative (HER2−) breast carcinoma (BC) in elderly… 
Review
2011
Review
2011
P3-14-15: Non-Randomized, Open Label Phase II Trial Evaluating the Safety and Efficacy of Taxotere (T) Followed by Myocet (M) + Cyclophosphamide (C) as First-Line Treatment for HER2−Negative Breast…
Background Breast cancer is the most common malignancy in females in Europe and is the most common cause of cancer mortality in… 
2010
2010
First-line treatment of metastatic breast cancer with the use of liposomal doxorubicin (Myocet ® ) in a female patient with ischaemic heart disease and cardiac dysrhythmia
Antracykliny są lekami o duzej skuteczności w leczeniu chorych z rozsianym rakiem piersi. Cześc pacjentek obciązonych… 
2010
2010
A nem pegilált liposzomális doxorubicin (Myocet®), mint a szabad doxorubicin kevésbé kardiotoxikus alternatívája
Valoszinűleg az antraciklinek tekintendők az emlőrak – valamint az egyeb szolid tumorok es az egyes malignus hematologiai… 
2010
2010
Substituting doxorubicin with nonpegylated liposomal doxorubicin (NPLD) in adjuvant/primary chemotherapy for early breast cancer, impact in cardiac function: A pilot study.
616 Background: NPLD (Myocet, Cephalon UK Ltd) is effective for the treatment of metastatic breast cancer and is less cardiotoxic… 
2009
2009
Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer.
Abstract #3149 Objective: the aims of the study are to assess activity and safety of liposomal doxorubicin (Myocet®) in… 
2009
2009
A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCET®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer.
Abstract #3156 The objective of the phase II study is to evaluate the cardiotoxicity, general safety, and efficacy of non… 
2001
2001
Drug-Drug Interactions Arising From the Use of Liposomal Vincristine in Combination with Other Anticancer Drugs
Chemotherapeutic agents for cancer treatment typically are given as combination therapies from multiple classes of drugs (1–4… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)